=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 12:22:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3659 TO ITERATE

100.0% PROCESSED 3659 ITERATIONS 1967 ANSWERS
SEARCH TIME: 00.00.01

L3 1967 SEA SSS FUL L1

=> s l3 and bipheny?
397243 BIPHENY?
L11 217 L3 AND BIPHENY?

=> d scan

L11 217 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN **2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4'-(4-pyridinyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI)**
MF C23 H22 N2 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.03	279.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'CAPLUS' ENTERED AT 12:28:54 ON 18 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 17 Apr 2005 (20050417/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l11
L12           8 L11

=> s l12 andpy<2002
MISSING OPERATOR L12 ANDPY<2002
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l12 and py<2002
      21606749 PY<2002
L13           4 L12 AND PY<2002

=> d bib abs hitstr 4

L13  ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   1999:350651  CAPLUS
DN   131:18929
TI   Preparation of arylsulfonylheterocyclylhydroxamic acids and related
     compounds as matrix metalloprotease inhibitors
IN   Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary
     A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman,
     Daniel P.
PA   G.D. Searle and Co., USA
SO   PCT Int. Appl., 840 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 9925687            A1    19990527    WO 1998-US23242         19981112 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2306460            AA    19990527    CA 1998-2306460         19981112 <--
     AU 9913732            A1    19990607    AU 1999-13732           19981112 <--
     AU 756150             B2    20030102
     BR 9814643            A     20001003    BR 1998-14643           19981112 <--
     EP 1042290            A1    20001011    EP 1998-957485          19981112 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
     JP 2001523662         T2    20011127    JP 2000-521071          19981112 <--
     NZ 503485             A     20021025    NZ 1998-503485          19981112
     ZA 9810412            A     19991209    ZA 1998-10412           19981113 <--
     US 2001014688         A1    20010816    US 1998-191129          19981113 <--
     NO 2000002469         A     20000712    NO 2000-2469            20000512 <--
     US 6541489            B1    20030401    US 2000-554082          20000731
     US 2002177588         A1    20021128    US 2001-954451          20010917
     US 6750233            B2    20040615
     US 2004048852         A1    20040311    US 2003-337942          20030107
PRAI US 1997-66007P        P     19971114
     US 1998-95347P        P     19980804
     US 1998-95501P        P     19980806
     US 1998-101080P       P     19980918
     WO 1998-US23242       W     19981112
     US 1999-256948        B3    19990224
     US 2000-554082        A3    20000731
OS   MARPAT 131:18929
GI
```



I

AB A process for treating conditions associated with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring containing 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixture of Et N-tert-butoxycarbonylisonipecotate (preparation given) and LDA in THF at -60° to room temperature to give 405 sulfide, which was oxidized with m-ClC6H4CO(OOH) to give 59% sulfone. The Et ester was saponified with NaOH in EtOH/H2O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aqueous NH2OH to give title compound (I). I inhibited MMP-2 with IC50 = 0.2 nM.

IT **226390-38-1P 226393-32-4P 226393-35-7P**
226393-38-0P 226393-41-5P 226393-43-7P
226393-46-0P 226393-48-2P 226393-50-6P
226393-52-8P 226393-54-0P 226393-57-3P
226393-58-4P 226393-61-9P 226393-63-1P
226393-64-2P 226393-66-4P 226394-21-4P
226394-22-5P 226394-23-6P 226394-24-7P
226394-25-8P 226394-26-9P 226394-27-0P
226394-28-1P 226394-34-9P 226394-40-7P
226394-43-0P 226394-45-2P 226394-47-4P
226394-49-6P 226394-51-0P 226394-53-2P
226394-55-4P 226394-57-6P 226394-59-8P
226394-61-2P 226394-63-4P 226394-65-6P
226394-67-8P 226394-69-0P 226394-71-4P
226394-73-6P 226394-75-8P 226394-77-0P
226394-79-2P 226394-81-6P 226394-83-8P
226394-85-0P 226394-87-2P 226394-88-3P
226394-89-4P 226394-90-7P 226394-92-9P
226394-93-0P 226394-94-1P 226394-95-2P
226394-97-4P 226394-98-5P 226395-00-2P
226395-01-3P 226395-02-4P 226395-25-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)

RN 226390-38-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-([1,1'-biphenyl]-4-yloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-32-4 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-([1,1'-biphenyl]-4-ylsulfonyl)tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-35-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(3'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-38-0 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-41-5 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-43-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4'-[2-(1-pyrrolidinyl)ethoxy][1,1'-biphenyl]-4-yl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226393-42-6
CMF C24 H30 N2 O6 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 226393-46-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-48-2 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-50-6 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-52-8 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4'-fluoro-3'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-54-0 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(3',4'-dimethyl[1,1'-biphenyl]-4-yl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

<------User Break------>

RN 226394-51-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[3'-(propylamino)[1,1'-biphenyl]-4-yl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226394-50-9
CMF C21 H26 N2 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 226394-53-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[4'-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl][1,1'-biphenyl]-3-yl]-, ethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226394-52-1
CMF C26 H32 N2 O7 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d bib hitstr 3

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:608722 CAPLUS
DN 133:193079
TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors
IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidahar N.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 851 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050396	A1	20000831	WO 2000-US2518	20000222 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001039287	A1	20011108	US 1999-256948	19990224 <--
	CA 2371876	AA	20000831	CA 2000-2371876	20000222 <--
	AU 2000034785	A5	20000914	AU 2000-34785	20000222 <--
	EP 1230219	A1	20020814	EP 2000-913317	20000222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000008491	A	20020917	BR 2000-8491	20000222
	JP 2002537378	T2	20021105	JP 2000-600979	20000222
	NZ 513648	A	20040227	NZ 2000-513648	20000222
	NO 2001003963	A	20011023	NO 2001-3963	20010815 <--
	ZA 2001006780	A	20020816	ZA 2001-6780	20010816
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
PRAI	US 1999-256948	A	19990224		
	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-95501P	P	19980806		
	US 1998-101080P	P	19980918		
	WO 2000-US2518	W	20000222		

OS MARPAT 133:193079
IT **226390-38-1P 226393-32-4P 226393-35-7P**
226393-38-0P 226393-41-5P 226393-43-7P
226393-46-0P 226393-48-2P 226393-50-6P
226393-52-8P 226393-54-0P 226393-57-3P
226393-58-4P 226393-61-9P 226393-63-1P
226393-64-2P 226393-66-4P 226394-21-4P
226394-22-5P 226394-23-6P 226394-24-7P
226394-25-8P 226394-26-9P 226394-27-0P
226394-28-1P 226394-34-9P 226394-40-7P
226394-43-0P 226394-45-2P 226394-47-4P
226394-49-6P 226394-51-0P 226394-53-2P
226394-55-4P 226394-57-6P 226394-59-8P

226394-61-2P 226394-63-4P 226394-65-6P
226394-67-8P 226394-69-0P 226394-71-4P
226394-73-6P 226394-75-8P 226394-77-0P
226394-79-2P 226394-81-6P 226394-83-8P
226394-85-0P 226394-87-2P 226394-88-3P
226394-89-4P 226394-90-7P 226394-92-9P
226394-93-0P 226394-94-1P 226394-95-2P
226394-97-4P 226394-98-5P 226395-00-2P
226395-01-3P 226395-02-4P 226395-25-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)

RN 226390-38-1 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-([1,1'-biphenyl]-4-yloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-32-4 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-([1,1'-biphenyl]-4-ylsulfonyl)tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-35-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(3'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-38-0 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226393-41-5 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 226393-43-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4'-[2-(1-pyrrolidinyl)ethoxy][1,1'-biphenyl]-4-yl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226393-42-6
CMF C24 H30 N2 O6 S

PAGE 1-A





CM 2

CRN 76-05-1
CMF C2 H F3 O2

<------User Break------>
)XH

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 226394-47-4 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[3'-(1-piperazinyl)[1,1'-biphenyl]-4-yl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226394-46-3
CMF C22 H27 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d bib hitstr 2

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:824220 CAPLUS
DN 134:17399
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitors
IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffrey N.; Decrescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Stephen A.; Li, Madeleine Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 616 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000069821	A1	20001123	WO 2000-US6719	20000515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6750228	B1	20040615	US 2000-570731	20000512
CA 2372934	AA	20001123	CA 2000-2372934	20000515 <--
EP 1183239	A1	20020306	EP 2000-930088	20000515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010562	A	20030610	BR 2000-10562	20000515
JP 2003520196	T2	20030702	JP 2000-618238	20000515
AU 766792	B2	20031023	AU 2000-47970	20000515
NZ 515217	A	20040430	NZ 2000-515217	20000515
ZA 2001009006	A	20021202	ZA 2001-9006	20011031
NO 2001005543	A	20020110	NO 2001-5543	20011113
PRAI US 1999-311837	A	19990514		
US 2000-570731	A	20000512		
US 1997-66007P	P	19971114		
US 1998-95347P	P	19980804		
US 1998-101080P	P	19980918		
US 1999-256948	B2	19990224		
WO 2000-US6719	W	20000515		

OS MARPAT 134:17399
IT **308823-70-3P 308827-37-4P 308827-51-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aromatic sulfone hydroxamic acids as metalloprotease inhibitors)
RN 308823-70-3 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-[4-([1,1'-biphenyl]-2-ylmethoxy)-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 308827-37-4 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 308827-51-2 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[(2'-cyano[1,1'-biphenyl]-4-yl)methoxy]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 1

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:485162 CAPLUS
DN 141:38534
TI Preparation of aromatic sulfone hydroxamic acid metalloprotease inhibitors
IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffrey N.; Decrescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Li, Madeleine H.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.
PA Pharmacia Corporation, USA
SO U.S., 403 pp., Cont.-in-part of U.S. Ser. No. 311,837.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6750228	B1	20040615	US 2000-570731	20000512
	US 2001014688	A1	20010816	US 1998-191129	19981113 <--
	US 2001039287	A1	20011108	US 1999-256948	19990224 <--
	CA 2372934	AA	20001123	CA 2000-2372934	20000515 <--
	WO 2000069821	A1	20001123	WO 2000-US6719	20000515 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1183239	A1	20020306	EP 2000-930088		20000515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 2000010562	A	20030610	BR 2000-10562		20000515
JP 2003520196	T2	20030702	JP 2000-618238		20000515
AU 766792	B2	20031023	AU 2000-47970		20000515
NZ 515217	A	20040430	NZ 2000-515217		20000515
US 2002177588	A1	20021128	US 2001-954451		20010917
US 6750233	B2	20040615			
ZA 2001009006	A	20021202	ZA 2001-9006		20011031
NO 2001005543	A	20020110	NO 2001-5543		20011113
US 2003073718	A1	20030417	US 2001-989943		20011121
US 6683093	B2	20040127			
US 2004209914	A1	20041021	US 2003-730403		20031208
US 2004235818	A1	20041125	US 2003-747796		20031229
PRAI US 1997-66007P	P	19971114			
US 1998-95347P	P	19980804			
US 1998-101080P	P	19980918			
US 1999-256948	B2	19990224			
US 1999-311837	A2	19990514			
US 1998-95501P	P	19980806			
US 1998-186410	B2	19981105			
US 1998-191129	B2	19981113			
US 2000-570731	A	20000512			
WO 2000-US6719	W	20000515			
US 2001-989943	A3	20011121			

OS MARPAT 141:38534

IT **308823-70-3P 308827-37-4P 308827-51-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aromatic sulfone hydroxamic acids as metalloprotease inhibitors)

RN 308823-70-3 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-([1,1'-biphenyl]-2-ylmethoxy)-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 308827-37-4 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(4'-fluoro[1,1'-biphenyl]-2-yl)-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 308827-51-2 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[(2'-cyano[1,1'-biphenyl]-4-yl)methoxy]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 12:22:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3659 TO ITERATE

100.0% PROCESSED 3659 ITERATIONS 1967 ANSWERS
SEARCH TIME: 00.00.01

L3 1967 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	162.19	162.40

FILE 'CAPLUS' ENTERED AT 12:22:52 ON 18 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Apr 2005 VOL 142 ISS 17